Compare FUL & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUL | ADPT |
|---|---|---|
| Founded | 1887 | 2009 |
| Country | United States | United States |
| Employees | N/A | 624 |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 2007 | 2019 |
| Metric | FUL | ADPT |
|---|---|---|
| Price | $63.71 | $17.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $68.40 | $17.78 |
| AVG Volume (30 Days) | 600.5K | ★ 2.0M |
| Earning Date | 03-25-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | 19.57 | ★ 63.89 |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $2,897,000,000.00 | $276,976,000.00 |
| Revenue This Year | $4.96 | $3.98 |
| Revenue Next Year | $4.00 | $22.72 |
| P/E Ratio | $167.37 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $48.71 | $9.96 |
| 52 Week High | $68.63 | $20.76 |
| Indicator | FUL | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 61.51 |
| Support Level | $57.33 | $14.87 |
| Resistance Level | $65.37 | $17.72 |
| Average True Range (ATR) | 2.19 | 1.22 |
| MACD | 0.29 | 0.30 |
| Stochastic Oscillator | 79.57 | 66.16 |
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives, and Construction Adhesives. It generates the maximum revenue from hygiene, health, and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven, and hygiene (disposable diapers, feminine care, and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.